Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 7/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15867803 | 0.91 | NAMPT (0.45) | MEN1KMT2ALIPGCNR1QDPR | |
| SCHEMBL18500637 | 0.84 | NAMPT (0.40) | MEN1KMT2ALIPGCNR1QDPR | |
| SCHEMBL19297505 | 0.83 | QDPR (0.42) | LIPGQDPRNAMPTLPL | |
| SCHEMBL12779997 | 0.81 | NAMPT (0.53) | NAMPT | |
| SCHEMBL28954013 | 0.80 | P2RX7 (0.43) | MEN1KMT2AMAPK1CCNT1CDK9 | |
| SCHEMBL16922689 | 0.79 | MEN1 (0.55) | MEN1KMT2ACNR1QDPRNAMPT | |
| SCHEMBL17897342 | 0.77 | QDPR (0.54) | LIPGQDPRLPL | |
| SCHEMBL25221340 | 0.76 | KDM4E (0.41) | MEN1KMT2ALIPGNAMPTLPL | |
| SCHEMBL14167571 | 0.75 | AKR1C3 (0.52) | KMT2AMAPK1ROCK1 | |
| SCHEMBL16920229 | 0.75 | CNR1 (0.55) | MEN1KMT2ACNR1QDPRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9567330-B2 | Azabenzimidazole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567330-B2 | Azabenzimidazole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | MEN1 2759/4885KMT2A 1137/4885LIPG 4187/4885 |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | MEN1 2759/4885KMT2A 1137/4885LIPG 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.